| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1230 | 949 | 67 |
| Full Text Views | 6 | 1 | 0 |
| PDF Downloads | 5 | 2 | 0 |
Exogenous Interferon Administration in Experimental Leishmaniasis: In Vivo and in Vitro Studies
David J. Wyler
David J. Wyler
Division of Geographic Medicine, Tufts-New England Medical Center, Interferon Laboratory, Sloan-Kettering Institute for Cancer Research, Boston, Massachusetts 02111
Search for other papers by David J. Wyler in
Current site
Google Scholar
PubMed
Search for other papers by David J. Wyler in
Current site
Google Scholar
PubMed
Li-Fang Liang
Li-Fang Liang
Division of Geographic Medicine, Tufts-New England Medical Center, Interferon Laboratory, Sloan-Kettering Institute for Cancer Research, Boston, Massachusetts 02111
Search for other papers by Li-Fang Liang in
Current site
Google Scholar
PubMed
Search for other papers by Li-Fang Liang in
Current site
Google Scholar
PubMed
Ethel Downey
Ethel Downey
Division of Geographic Medicine, Tufts-New England Medical Center, Interferon Laboratory, Sloan-Kettering Institute for Cancer Research, Boston, Massachusetts 02111
Search for other papers by Ethel Downey in
Current site
Google Scholar
PubMed
Search for other papers by Ethel Downey in
Current site
Google Scholar
PubMed
Mathilde Krim
Mathilde Krim
Division of Geographic Medicine, Tufts-New England Medical Center, Interferon Laboratory, Sloan-Kettering Institute for Cancer Research, Boston, Massachusetts 02111
Search for other papers by Mathilde Krim in
Current site
Google Scholar
PubMed
Search for other papers by Mathilde Krim in
Current site
Google Scholar
PubMed
The potential feasibility of using exogenously administered human interferon for the treatment of selected cases of leishmaniasis prompted us to study the effects of murine interferon on the course of Leishmania tropica infection in C57Bl/6 mice. L cell-derived mouse interferon was administered daily by intraperitoneal (1,000 and 10,000 U) or intralesional (100 U) injection in mice inoculated into footpads with L. tropica amastigotes. Footpad swelling and tissue parasite density were assessed over the course of infection. Interferon treatment did not significantly affect these clinical and parasitological parameters. Furthermore, addition of interferon (100–100,000 U) to cultures of amastigote-infected mouse peritoneal macrophages or to axenic cultures of promastigotes did not affect replication. We conclude that interferon lacks intrinsic antileishmanial activity and does not significantly enhance host defense against Leishmania.
Author Notes
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1230 | 949 | 67 |
| Full Text Views | 6 | 1 | 0 |
| PDF Downloads | 5 | 2 | 0 |